ASCO Congratulates Robert M. Califf, MD, on Confirmation as FDA Commissioner

Statement By Howard A. “Skip” Burris III, MD, FACP, FASCO Board Chair of the Association for Clinical Oncology (ASCO)
February 15, 2022

"The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA). 

"As a former FDA Commissioner, Dr. Califf has demonstrated a deep commitment to protecting public health and has experience leading large and complex organizations, which is critical as we continue to respond to an unprecedented global pandemic. With four decades of experience in clinical and translational medicine Dr. Califf is extraordinarily well-suited to lead the FDA in assuring that treatments and medical devices are safe and effective for patients. We look forward to working with him to modernize and streamline clinical trials so they are accessible, affordable, and equitable.

"An advocate for using real-world data (RWD) and real-world evidence (RWE) in clinical studies, Dr. Califf understands the importance of quality evidence to continue the agency’s development of a RWE regulatory framework. We’re also encouraged that Dr. Califf is a longtime supporter of tobacco control, and we are hopeful that we can accelerate progress towards ending tobacco-related disease, including cancer.

"We look forward to continuing our productive history of collaborating with Dr. Califf and the FDA in reducing cancer incidence, advancing treatment options, and improving the lives of people with cancer.”